Septerna (NASDAQ:SEPN) Shares Down 5% – Should You Sell?

Posted by Micah Haroldson on Jan 1st, 2025

Septerna, Inc. (NASDAQ:SEPN – Get Free Report) shares were down 5% during mid-day trading on Monday . The stock traded as low as $24.07 and last traded at $24.07. Approximately 67,634 shares were traded during trading, a decline of 79% from the average daily volume of 324,280 shares. The stock had previously closed at $25.33.

Wall Street Analyst Weigh In

SEPN has been the topic of several research reports. Cantor Fitzgerald started coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price target for the company. TD Cowen started coverage on Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price objective for the company.

Check Out Our Latest Stock Report on SEPN

Septerna Stock Performance

The firm’s fifty day simple moving average is $23.77.

Insider Activity at Septerna

In other news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was acquired at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the purchase, the insider now directly owns 6,215,591 shares of the company’s stock, valued at $111,880,638. This represents a 6.34 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

About Septerna

(Get Free Report)

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.